REG - Smith & Nephew Plc - Euro Bond Issue

Smith & NephewAnnouncement

05/10/2022 09:33

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221005:nRSE8417Ba&default-theme=true

RNS Number : 8417B  Smith & Nephew Plc  05 October 2022

Smith & Nephew plc

 

5 October 2022

 

SMITH+NEPHEW PRICES EURO BOND ISSUE

 

Smith & Nephew plc (LSE:SN, NYSE:SNN) ("Smith+Nephew") has completed the
pricing of Euro 500,000,000 4.565% Notes due 2029 (the "Notes").

 

The proceeds to Smith+Nephew (after expenses and underwriting discounts) of
Euro 495,955,637 from the Notes will be used for general corporate purposes,
including repayment of the amounts outstanding under Smith+Nephew's €265
million term loan due April 2023 and €223 million term loan due May 2023,
including fees and expenses related thereto.

 

The offering is scheduled to close on 11 October 2022, subject to the
satisfaction of customary conditions.

 

Smith+Nephew has filed a registration statement (including a prospectus) with
the U.S. Securities and Exchange Commission (the "SEC") for the offering to
which this communication relates.  Investors should read the prospectus in
such registration statement and other documents Smith+Nephew has filed with
the SEC for more complete information about Smith+Nephew and this offering.
You may get these documents for free by visiting the SEC web site at
www.sec.gov.  Alternatively, you may obtain a copy of the Prospectus and
Preliminary Prospectus Supplement from Merrill Lynch International by calling
toll free at +1-800-294-1322; Mizuho International plc by calling collect at
+44 (0) 20 7248 3920; SMBC Nikko Capital Markets Limited by calling collect at
+44 (0) 20 4507 5017; or Société Générale by calling collect at +33 (0) 1
42 13 32 16.

 

This press release does not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor will there be any sale of securities in
any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

 

Enquiries

 Investors
 Andrew Swift                      +44 (0) 1923 477433
 Smith+Nephew

 Media
 Charles Reynolds                  +44 (0) 1923 477314
 Smith+Nephew

 Susan Gilchrist / Ayesha Bharmal  +44 (0) 20 7404 5959
 Brunswick

 

Legal Entity Identifier:  213800ZTMDN8S67S1H61

 

 

About Smith+Nephew

 

Smith+Nephew is a portfolio medical technology company that exists to restore
people's bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 18,000 employees
deliver this mission every day, making a difference to patients' lives
through the excellence of our product portfolio, and the invention and
application of new technologies across our three global franchises of
Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

 

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent
of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are
used to refer to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.

 

Forward-looking statements

 

This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading profit margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan", "intend",
"anticipate", "well-placed", "believe", "estimate", "expect", "target",
"consider" and similar expressions are generally intended to identify
forward-looking statements. Forward-looking statements involve known and
unknown risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or implied by the
statements. For Smith+Nephew, these factors include: risks related to the
impact of COVID, such as the depth and longevity of its impact, government
actions and other restrictive measures taken in response, material delays and
cancellations of elective procedures, reduced procedure capacity at medical
facilities, restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of COVID;
economic and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers (including, without
limitation, as a result of COVID); price levels for established and innovative
medical devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product defects or
recalls or other problems with quality management systems or failure to comply
with related regulations; litigation relating to patent or other claims; legal
compliance risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID); competition for
qualified personnel; strategic actions, including acquisitions and
dispositions, our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to market
developments; relationships with healthcare professionals; reliance on
information technology and cybersecurity; and numerous other matters that
affect us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's
most recent annual report on Form 20-F, for a discussion of certain of these
factors. Any forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update or revise
any forward-looking statement to reflect any change in circumstances or in
Smith+Nephew's expectations.

 

(◊) Trademark of Smith+Nephew. Certain marks registered with the US Patent
and Trademark Office.

 

United Kingdom

 

The communication of the prospectus supplement and the accompanying prospectus
and any other documents or materials relating to the Notes is not being made,
and such documents and/or materials have not been approved, by an authorized
person for the purposes of Section 21 of the United Kingdom's Financial
Services and Markets Act 2000, as amended (the "FSMA"). Accordingly, such
documents and/or materials are not being distributed to, and must not be
passed on to, the general public in the United Kingdom. Such documents and/or
materials are only being distributed to, and are only directed at, persons
outside the United Kingdom or in the United Kingdom to persons that (i) have
professional experience in matters relating to investments falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended, the "Order"), (ii) who fall within Article
49(2)(a) to (d) of the Order or (iii) to whom it may otherwise lawfully be
communicated (all such persons together being referred to as "relevant
persons"). The Notes are only available to, and any invitation, offer or
agreement to purchase or otherwise acquire such Notes will be engaged in only
with, relevant persons.

 

Prohibition of Sales to United Kingdom Retail Investors

 

The Notes are not intended to be offered, sold or otherwise made available to
and should not be offered, sold or otherwise made available to any retail
investor in the United Kingdom. For these purposes, a retail investor means a
person who is one (or more) of: (i) a retail client, as defined in point (8)
of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law
in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018
(the "EUWA"); or (ii) a customer within the meaning of the provisions of the
FSMA and any rules or regulations made under the FSMA to implement Directive
(EU) 2016/97 (as amended,, where that customer would not qualify as a
professional client, as defined in point (8) of Article 2(1) of Regulation
(EU) No 600/2014 as it forms part of domestic law in the United Kingdom by
virtue of the EUWA ("UK MiFIR"). Consequently no key information document
required by Regulation (EU) No 1286/2014 as it forms part of domestic law in
the United KIngdom by virtue of the EUWA (the "UK PRIIPs Regulation") for
offering or selling the Notes or otherwise making them available to retail
investors in the UK has been prepared and therefore offering or selling the
Notes or otherwise making them available to any retail investor in the United
Kingdom may be unlawful under the UK PRIIPs Regulation.

 

Prohibition of Sales to EEA Retail Investors

 

The Notes are not intended to be offered, sold or otherwise made available to
and should not be offered, sold or otherwise made available to any retail
investor in the European Economic Area (the "EEA"). For these purposes, a
retail investor means a person who is one (or more) of: (i) a retail client as
defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended,
"MiFID II); or (ii) a customer within the meaning of Directive (EU) 2016/97
(as amended, the "Insurance Distribution Directive") where that customer would
not qualify as a professional client as defined in point (10) of Article 4(1)
of MiFID II. Consequently no key information document required by Regulation
(EU) No 1286/2014 (as amended, the "PRIIPs Regulation") for offering or
selling the Notes or otherwise making them available to retail investors in
the EEA has been prepared and therefore offering or selling the Notes or
otherwise making them available to any retail investor in the EEA may be
unlawful under the PRIIPs Regulation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODFIFEEIDLEIIF